14703-79-8

Usage

InChI:InChI=1/C7H8N2O3/c1-8-6-4-5(10)2-3-7(6)9(11)12/h2-4,8,10H,1H3

Upstream product

• 491-11-2 3-chloro-4-nitrophenol 
• 74-89-5 methylamine 
• 394-41-2 3-fluoro-4-nitrophenol 

Downstream Products

• 63810-42-4 [3-(N-methylamino)4-nitro] phenyl N,N-diethylcarbamylmethyl ether 
• 50591-23-6 1-methyl-1H-benzo[d]imidazol-6-ol 

Relevant academic research and scientific papers

RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS

The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.

Hair dye compositions and new compounds useful therein

Novel compounds of the general formula STR1 wherein Z represents a substituted lower alkyl radical; each of R1 and R2 is hydrogen atom, a lower alkyl or a substituted lower alkyl identical with or different from Z and the functional groups NO2 and NR1 R2 can occupy all ring positions in relation to OZ, with the exception that if Z is β-hydroxyethyl, --NO2 is in the 4 position and --N(R1)(R2) is in the 2 position then either R1 or R2 is other than hydrogen. The novel compounds are for dyeing human hair in a variety of yellow shades. The compounds of formula (I) may be used as aqueous or water-alcohol solutions to form dye compositions for dyeing human hair.